Breaking News, Trials & Filings

Trials & Filings in Brief: Sept. 27, 2013

CSL Behring, Durata, Novartis, Zalicus

Filings
CSL Behring’s Hizentra cleared to treat PID in Japan . . . read more

Durata files NDA for ABSSSI treatment . . . read more

Zalicus gets orphan designation for Z160 . . . read more

Post-Approval
Good data for Novartis’ Lucentis . . . read more

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters